Blueshift Asset Management LLC Acquires 218,804 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Blueshift Asset Management LLC grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 834.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 245,013 shares of the company’s stock after buying an additional 218,804 shares during the quarter. Hims & Hers Health comprises about 1.1% of Blueshift Asset Management LLC’s investment portfolio, making the stock its 9th largest holding. Blueshift Asset Management LLC’s holdings in Hims & Hers Health were worth $4,513,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth $111,000. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on HIMS. Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $20.71.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the transaction, the insider now directly owns 193,980 shares in the company, valued at $4,306,356. This represents a 3.72 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $30.67 on Wednesday. The business has a 50 day simple moving average of $20.85 and a 200-day simple moving average of $19.44. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $31.68. The stock has a market capitalization of $6.70 billion, a PE ratio of 69.69 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the business earned ($0.04) EPS. The business’s revenue was up 77.1% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.